Drug Trial Radar · NCT05287113
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Nov 14, 2022
Primary completion
Mar 14, 2025
Study completion Jun 23, 2026
Sponsor
- Lead sponsor
- Incyte Biosciences International SàrlIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Mar 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Conditions
- Head and Neck Cancer
Interventions
RetifanlimabDrug
Retifanlimab 500mg will be administered intravenously every 4 weeks.
INCAGN02385Drug
INCAGN02385 350mg will be administered intravenously every 2 weeks.
INCAGN02390Drug
INCAGN02390 400 mg will be administered intravenously every 2 weeks.
PlaceboDrug
Placebo will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progeression-free Survival (PFS)Time frame: up to 738 days
Locations
91 sites in 14 countries. Site status is shown where the registry gives one.
Mayo Clinic Rochester
Scottsdale, Arizona
City of Hope National Medical Center
Duarte, California
City of Hope Orange County
Irvine, California
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California
City of Hope-Antelope Valley
Lancaster, California
Innovative Clinical Research Institute
Long Beach, California
City of Hope National Medical Center
Long Beach, California
University of California San Francisco Comprehensive Cancer Center
San Francisco, California
Georgetown University
Washington D.C., District of Columbia
Mayo Clinic Jacksonville
Jacksonville, Florida
Blessed Health Care
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
University of Illinois At Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas Hospital Authority
Kansas City, Kansas
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Cancer Center
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Huntsman Cancer Institute At University of Utah
Salt Lake City, Utah
University of Virginia - Emily Couric Clinical Cancer Center
Charlottesville, Virginia
Kadlec Clinic Hematology and Oncology
Kennewick, Washington
Grand Hospital de Charleroi
Charleroi, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
Gza Sint Augustinus
Wilrijk, Belgium
McGill University Health Centre/Glen Site/Cedars Cancer Centre
Montreal, Quebec, Canada
Chum Hospital Notre Dame
Montreal, Quebec, Canada
McGill University Jewish General Hospital
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
Institut Curie
Paris, France
Centre Eugene Marquis
Rennes, France
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau
Saint-Herblain, France
Icans - Institut de Cancerologie Strasbourg Europe
Strasbourg, France
Jsc Evex Hospitals
K'ut'aisi, Georgia
New Hospitals
Tbilisi, Georgia
Jsc Evex Corporation-Caraps Medline
Tbilisi, Georgia
Ltd Cancer Research Centre
Tbilisi, Georgia
University of Cologne
Cologne, Germany
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.